FDA Drug Safety Communication: Benicar

Benicar benefits continue to outweigh its potential risks

/ Author:  / Reviewed by: Joseph V. Madia, MD

After reviewing the results of the ROADMAP and ORIENT trials, the FDA has determined that the benefits of Benicar" data-scaytid="1">Benicar continue to outweigh its potential risks when used for the treatment of patients with high blood pressure according to the drug label. Benicar is not recommended as a treatment to delay or prevent protein in the urine (microalbuminuria) in diabetic patients.

Patients should consult their healthcare professional if they have any questions or concerns about taking Benicar.

Daiichi Sankyo, the makers of Benicar, have agreed to work with the FDA to perform additional studies, as well as conduct additional analyses of completed clinical studies, to obtain more complete information about the cardiovascular risks or benefits of Benicar in various clinical settings. FDA will update the public when new information is available.

Reviewed by: 
Review Date: 
July 26, 2011